Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
CAMBRIDGE, Mass., May 01, 2018 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), today announced that it will release its financial results for the first quarter ended March 31, 2018 and provide a corporate update before the U.S. financial markets open on Tuesday, May 8, 2018.
Management will host a conference call on that date at 8:00 a.m. ET to discuss these results and provide an update on the company. To access the call, please dial (877) 224-9084 (domestic) or (720) 545-0022 (international) prior to the scheduled conference call time and provide the access code 7665388. A live webcast of the call will be available on the "Investors" section of the company's website, www.momentapharma.com. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
[email protected]
